Short Interest in The Oncology Institute, Inc. (NASDAQ:TOI) Declines By 22.8%

The Oncology Institute, Inc. (NASDAQ:TOI) saw a significant decrease in short interest in September. As of September 15th, there was short interest totalling 233,000 shares, a decrease of 22.8% from the August 31st total of 301,700 shares. Based on an average daily volume of 131,000 shares, the days-to-cover ratio is presently 1.8 days. Currently, 0.7% of the shares of the company are sold short.

Institutional Investors Weigh In On Oncology Institute

A number of institutional investors have recently added to or reduced their stakes in the company. Tiff Advisory Services LLC lifted its holdings in Oncology Institute by 235.1% in the 2nd quarter. Tiff Advisory Services LLC now owns 1,418,685 shares of the company’s stock valued at $653,000 after acquiring an additional 995,280 shares during the last quarter. Kent Lake Capital LLC boosted its holdings in Oncology Institute by 9.4% during the first quarter. Kent Lake Capital LLC now owns 1,186,713 shares of the company’s stock worth $1,875,000 after buying an additional 101,542 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Oncology Institute by 142.3% during the second quarter. Renaissance Technologies LLC now owns 339,400 shares of the company’s stock worth $156,000 after buying an additional 199,300 shares in the last quarter. FourWorld Capital Management LLC acquired a new position in Oncology Institute in the first quarter worth approximately $396,000. Finally, Quattro Financial Advisors LLC bought a new position in shares of Oncology Institute in the first quarter valued at $88,000. 36.86% of the stock is currently owned by institutional investors and hedge funds.

Oncology Institute Price Performance

Shares of TOI opened at $0.31 on Friday. Oncology Institute has a one year low of $0.27 and a one year high of $2.66. The stock’s fifty day moving average is $0.39 and its 200-day moving average is $0.72. The company has a debt-to-equity ratio of 3.08, a quick ratio of 2.99 and a current ratio of 3.31. The firm has a market capitalization of $23.05 million, a price-to-earnings ratio of -0.38 and a beta of 0.61.

Oncology Institute (NASDAQ:TOI) last released its earnings results on Tuesday, August 13th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.07). The company had revenue of $98.58 million for the quarter, compared to analyst estimates of $103.31 million. Oncology Institute had a negative net margin of 18.86% and a negative return on equity of 136.63%. During the same period in the previous year, the business posted ($0.19) EPS.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.